1 option
Clinical review report : indication : indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupilumab (Dupixent) (Sanofi genzyme, a division of Sanofi-Aventis Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.
- Format:
- Book
- Author/Creator:
- Canadian Agency for Drugs and Technologies in Health, author, issuing body.
- Language:
- English
- Subjects (All):
- Outcome assessment (Medical care).
- Outcome assessment (Medical care)--Methodology.
- Physical Description:
- 1 online resource
- Edition:
- Version: Final.
- Place of Publication:
- Ottawa, ON : Canadian Agency for Drugs and Technologies in Health, 2020.
- Summary:
- The objective of this review was to perform a systematic review of the beneficial and harmful effects of dupilumab for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.
- Notes:
- Description based on publisher supplied metadata and other sources.
The Penn Libraries is committed to describing library materials using current, accurate, and responsible language. If you discover outdated or inaccurate language, please fill out this feedback form to report it and suggest alternative language.